ATC Group: A10BX16 Tirzepatide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BX16 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BX Other blood glucose lowering drugs, excl. insulins
5 A10BX16

Active ingredients in A10BX16

Active Ingredient

Tirzepatide is a long acting GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic α and β endocrine cells, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes. In addition, both GIP and GLP-1 receptors are expressed in the areas of the brain important to appetite regulation.

Related product monographs

Document Type Information Source  
 MOUNJARO Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 ZEPBOUND Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.